At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 34 enrolled
Drug / intervention
Chidamide +1 moredrug
Likely dose
Chidamide 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced Non-Small Cell Lung Cancer(NSCLC).
In Brief
A Phase 2 clinical trial evaluating Chidamide and Envafolimab for Non Small Cell Lung Cancer. Completed, enrolled 34 participants across 12 sites.
Detailed Summary
This study is to evaluate the preliminary efficacy and safety of Chidamide combined with Envafolimab in patients with PD-1 inhibitor resistant advanced NSCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedOct 2021
Enrollment StartNov 2021
Primary CompletionFeb 2023
Study CompletionMay 2024
TodayJul 2026
First PostedOct 5, 2021
Enrollment StartNov 23, 2021
Primary CompletionFeb 23, 2023
Study CompletionMay 16, 2024
TodayJul 1, 2026
Enrollment to primary: 1.3 yearsPosted 4.7 years ago
Interventions
Chidamidedrug
20mg or 30mg orally twice per week(BIW)
Envafolimabdrug
400mg subcutaneous infusions every 4 weeks